DAWN vs. AKRO, EWTX, MORF, KURA, ARDX, RCUS, LMAT, ZLAB, ANIP, and GYRE
Should you be buying Day One Biopharmaceuticals stock or one of its competitors? The main competitors of Day One Biopharmaceuticals include Akero Therapeutics (AKRO), Edgewise Therapeutics (EWTX), Morphic (MORF), Kura Oncology (KURA), Ardelyx (ARDX), Arcus Biosciences (RCUS), LeMaitre Vascular (LMAT), Zai Lab (ZLAB), ANI Pharmaceuticals (ANIP), and Gyre Therapeutics (GYRE). These companies are all part of the "medical" sector.
Akero Therapeutics (NASDAQ:AKRO) and Day One Biopharmaceuticals (NASDAQ:DAWN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, community ranking, profitability, risk and dividends.
Day One Biopharmaceuticals' return on equity of -29.59% beat Akero Therapeutics' return on equity.
88.0% of Day One Biopharmaceuticals shares are held by institutional investors. 9.7% of Akero Therapeutics shares are held by company insiders. Comparatively, 8.4% of Day One Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Akero Therapeutics has a beta of -0.38, indicating that its share price is 138% less volatile than the S&P 500. Comparatively, Day One Biopharmaceuticals has a beta of -1.48, indicating that its share price is 248% less volatile than the S&P 500.
Akero Therapeutics received 67 more outperform votes than Day One Biopharmaceuticals when rated by MarketBeat users. Likewise, 60.76% of users gave Akero Therapeutics an outperform vote while only 55.77% of users gave Day One Biopharmaceuticals an outperform vote.
Akero Therapeutics is trading at a lower price-to-earnings ratio than Day One Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Day One Biopharmaceuticals had 22 more articles in the media than Akero Therapeutics. MarketBeat recorded 28 mentions for Day One Biopharmaceuticals and 6 mentions for Akero Therapeutics. Akero Therapeutics' average media sentiment score of 0.56 beat Day One Biopharmaceuticals' score of 0.29 indicating that Day One Biopharmaceuticals is being referred to more favorably in the news media.
Akero Therapeutics currently has a consensus target price of $37.71, suggesting a potential upside of 99.13%. Day One Biopharmaceuticals has a consensus target price of $39.33, suggesting a potential upside of 195.07%. Given Akero Therapeutics' higher possible upside, analysts plainly believe Day One Biopharmaceuticals is more favorable than Akero Therapeutics.
Summary
Akero Therapeutics beats Day One Biopharmaceuticals on 7 of the 13 factors compared between the two stocks.
Get Day One Biopharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DAWN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Day One Biopharmaceuticals Competitors List
Related Companies and Tools
